Stay updated on Nivolumab + HF10 for Resectable Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The page revision identifier was updated from v3.6.0 to v3.6.2, indicating a minor update to the study record. No substantive content changes are indicated.
    Difference
    0.1%
    Check dated 2026-06-29T08:31:07.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The study page now indicates that recruitment is closed, reflecting that no further participants will be enrolled. This helps users understand that enrollment has ended and to adjust expectations accordingly.
    Difference
    0.8%
    Check dated 2026-06-15T05:52:47.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.5.5, replacing the previous v3.5.4, indicating a maintenance update to the page. This change does not modify the study details or other substantive content on the page.
    Difference
    0.1%
    Check dated 2026-06-08T05:07:10.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    - The related topics section no longer lists Melanoma and the MedlinePlus Genetics entry.
    Difference
    0.2%
    Check dated 2026-06-01T02:59:33.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    Revision on the page updated from v3.5.3 to v3.5.4, signaling a small patch or administrative update to the page metadata. No changes to the study content or user-facing information are indicated.
    Difference
    0.1%
    Check dated 2026-05-17T09:11:02.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Melanoma is added as a study topic and a Related topics section includes MedlinePlus Genetics, broadening navigational connections to related consumer health resources. These additions also connect the study to genetics information relevant to the condition.
    Difference
    0.2%
    Check dated 2026-05-10T08:54:21.000Z thumbnail image

Stay in the know with updates to Nivolumab + HF10 for Resectable Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.